Roivant Sciences

Roivant Sciences shares rose to an all-time high of $37.06 and are currently trading at $37.14, with a market capitalization of $26.19 billion. The stock has gained 206.52% over 12 months and 66.82% year-to-date; however, analysts view the stock as overvalued according to InvestingPro. In the first fiscal quarter, adjusted loss per share was $0.26 (better than the expected -$0.30), but revenue of $1.44 million fell short of forecasts. TD Cowen raised its price target from $41 to $50 and reiterated a "Buy" rating, citing potential catalysts in the second half of the year. » Más en de.investing.com

Three years ago Roivant Sciences traded at $11.50. A $10,000 investment would now be worth about $29,487 at a share price of $33.91, an increase of 194.87%. The company is valued at roughly $24.50 billion on the market; calculation does not account for stock splits or dividends. » Más en finanzen.net

A $10,000 investment in Roivant Sciences at the closing price on 13 July 2021 ($9.91) would have grown to $36,296.67 by 10 July 2026, based on a price of $35.97 per share and a performance of +262.97%. The company is recently reported to have a market capitalization of $25.92 billion. The calculation does not account for stock splits or dividends. » Más en finanzen.net